Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 2Prostatic Neoplasms 1HER2 Expression Gastric Cancer/Gastroesophageal Junction Adenocarcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Advanced Gastric Cancer 1

Interventions

Oxaliplatin 42Fluorouracil 27Capecitabine 24pembrolizumab 21S 1 (combination) 19Paclitaxel 19Leucovorin 16Nivolumab 13Docetaxel 13sintilimab 12Drug Therapy 12Trastuzumab 11tislelizumab 10Cisplatin 10Irinotecan 9Bevacizumab 8trastuzumab deruxtecan 7spartalizumab 7XELOX 7Surgical Procedures, Operative 7Radiotherapy 7Hyperthermic Intraperitoneal Chemotherapy 7Biopsy 7fludarabine 6disitamab vedotin 6Cyclophosphamide 6lenvatinib 5apatinib 5Specimen Handling 5Ramucirumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Stomach Neoplasms × SHR-1701 × Clear all
NCT07311408 2025-12-31

SHR-2554

China Medical University, China

Phase 2 Recruiting
40 enrolled
Gastrointestinal

Stomach Neoplasms

NCT07102901 2025-09-10

Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
351 enrolled
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡